Document Type

Article

Publication Date

3-2009

Publication Source

Bioorganic and Medicinal Chemistry

Abstract

We previously described a series of 314-helical β-peptides that bind the hDM2 protein and inhibit its interaction with a p53-derived peptide in vitro. Here we present a detailed characterization of the interaction of these peptides with hDM2 and report two new β-peptides in which non-natural side chains have been substituted into the hDM2-recognition epitope. These peptides feature both improved affinity and inhibitory potency in fluorescence polarization and ELISA assays. Additionally, one of the new β-peptides also binds the hDM2-related protein, hDMX, which has been identified as another key therapeutic target for activation of the p53 pathway in tumors.

Inclusive pages

2038-2046

ISBN/ISSN

0968-0896

Document Version

Postprint

Comments

The document available for download is the authors' accepted manuscript, provided in compliance with the publisher's policy on self-archiving. Permission documentation is on file. To read the version of record, use the DOI provided.

Publisher

Elsevier

Volume

17

Peer Reviewed

yes

Issue

5

Link to published version

Share

COinS